Clinipace Acquisition Pan-Asia CRO, Choice Pharma
Choice Pharma provides Clinipace a significant Pan-Asia footprint
Clinipace Worldwide announced its merger with Choice Pharma. The merger expands Clinipace's global reach to include new offices in Taiwan, China, Hong Kong, South Korea, Vietnam, Singapore, and Malaysia.
The combined company now has 640 staff in 30 countries, and experience managing over 1500+ clinical trials, and over 300 regulatory and strategic development engagements
There are no layoffs or office closings planned; and the new combined organization will continue to hire throughout the year. Terms of the transaction will not be disclosed.
This is the 5th acquisition by Clinipace in recent years.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
How the NIMBLE Study Supported Adherence With Quarterly Dosing of CemdisiranSeptember 18th 2025
Everything to Know About FDA’s Push Towards Radical Transparency in 2025September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient OutcomesSeptember 17th 2025
Managing Background Therapies in the NIMBLE Phase III TrialSeptember 17th 2025
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
